The International Expert Consensus on the Primary Therapy of Early Breast Cancer states that tamoxifen may be an acceptable option, but that aromatase inhibitors have shown superiority over tamoxifen in postmenopausal breast cancer [5]. This evidence concerns the gene CYP19A1 and breast carcinoma.